Johnson & Johnson to acquire Ollin Biosciences for $2.2 billion upfront

By Public Technologies
  • Johnson & Johnson agreed to acquire eye-disease drug developer Ollin Biosciences for $2.2 billion upfront.
  • Regulatory and commercial milestones could reach approximately $1.13 billion; closing is expected before the end of 2026.
  • The acquisition would add OLN324, an investigational bispecific antibody targeting wet age-related macular degeneration and diabetic macular edema, to its pipeline.
  • Blackstone Life Sciences will provide $750 million over multiple years to fully fund OLN324’s Phase 3 development, contingent on acquisition closing.
  • In return, Blackstone will be eligible for regulatory and sales milestone payments, as well as single-digit royalties.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Johnson & Johnson published the original content used to generate this news brief via Business Wire (Ref. ID: 20261116907414) on November 16, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk